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Introduction of percutaneous coronary inter-
vention (PCI) as a method of choice for the treat-
ment of patients with ST-segment elevation myo-
cardial infarction has brought a marked improve-
ment in short- and long-term prognosis in this group
of patients. Nevertheless, despite restoring com-
plete patency of epicardial coronary vessels, in
some patients the blood flow through these vessels
remains diminished to a lesser or greater degree.
This finding is due to post-reperfusion restriction
in the blood flow at the microcirculation level and
is known as the no-reflow phenomenon. Original-
ly, the phenomenon was recognized exclusively on
the basis of angiographic assessment of epicardial
flow, using the TIMI scale (Thrombolysis In Myo-
cardial Infarction). Progressively, angiographic as-
sessment was reinforced with estimation of micro-
circulation basing on TMPG (Thrombolysis In Myo-
cardial Infarction myocardial perfusion grade) and
cTFC (corrected Thrombolysis In Myocardial Inf-
arction frame count) [1].
No-reflow after myocardial infarction, as as-
sessed by angiography, is a strong predictor of ma-
jor cardiac complications, including heart failure,
malignant arrhythmias and cardiac death [2]. Unfa-
vourable clinical consequences and unpredictable
occurence of no-reflow are triggers for further re-
search upon its pathomechanism, risk factors, thera-
peutic options and further improvement of the tis-
sue perfusion assessment techniques [3].
Direct invasive coronary flow velocity meas-
urement, reflecting microvascular injury, may be
obtained by Doppler flow wires [4]. However, this
method due to its expensiveness and technical lim-
itations is more frequently applied in scientific set-
ting rather than in clinical practice.
An excellent method for microvascular per-
fusion assessment is myocardial contrast echocar-
diography (MCE). MCE assessment results are
closely related to myocyte viability and LV remo-
deling occurence at follow-up [5, 6]. The method is
widely available, may be performed in the bed-side
setting and is patient-friendly. Thus MCE may be
currently regarded as the gold standard to investi-
gate the no-reflow phenomenon [1].
The main limitation of other diagnostic methods,
including SPECT and MRI, is their unapplicability
immediately after recanalization of the infarct re-
lated artery in the catheterisation laboratory or in
the coronary care unit.
Olszowska et al. [6] looking for predictors of
no-reflow phenomenon compared clinical, hemody-
namic and electrocardiographic parameters in pa-
tients with acute myocardial infarction after PCI
characterised by reflow and those featuring no-re-
flow phenomenon. Post-intervention perfusion was
assessed with MCE, providing reliable and thorough
tissue perfusion estimation.
Several risk factors for no-reflow phenomenon
have been indentified so far, amongst which, the
coronary vessel closure time (period of time be-
tween the symptom onset and reperfusion) seems
to play the dominant role. It has been more than
20 years since Kloner et al. [7] proved on animal
models that prolongation of ischemia escalates the
damage of microcirculation.
Various mechanisms of such lesions have been
postulated. Oxygene-free radicals (OFR), which
appeare almost immediately following reperfusion,
produce lesions of coronary endothelium and thus,
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cause severe deficiency of endothelium derived
relaxing factor (ERDF) with all consequences of this
fact, such as relaxation of vascular smooth muscle
impairment and augmentation of platelet aggrega-
tion and neutrophil adherence [1, 8].
Prolonged ischemia compromises active trans-
membrane transport and leads to a raise in intrac-
ellular calcium levels. This phenomenon, addition-
ally amplified by sympathetic activation, produces
extensive coronary spasm at acute reperfusion [1].
Simultaneously, ischemia-related acidosis and
hyperosmolarity modify erythrocyte membrane,
which becomes more rigid. As the final result, de-
formability of red blood cells is decreased [9].
One of the most commonly suggested mecha-
nisms of no-reflow is embolization of the distal mi-
crovascular coronary circulation [9]. Microemboli-
zation may be due to defragmentation of an intra-
cornary thrombus (as commonly seen in acute
myocardial infarction) as well as due to small parti-
cles of atherosclerotic plaque (as seen in stable cor-
onary disease). The association of no-reflow with
longer ischemic time and worse initial TIMI flow
may indicate the presence of highly organized
thrombus burden with higher propensity for distal
embolization [2].  Such mechanism is additionally
advocated by the results of studies using intravas-
cular ultrasound [10] and intracoronary doppler [4]
as well as by reduction of prevalence of no-reflow
phenomenon after thrombectomy in acute myocar-
dial infarction as seen in some studies [11].
The equilibrium loss resulting from ischemia,
augmented by sudden blood flow restoration, induces
a complex inflammatory response, intensity of
which may be very diverse. The biological poten-
tial of the factors affecting this process is huge and
it may markedly increase the reperfusion injury.
Activated neutrophils adhere to the endothelium,
plug capillars in infarcted myocardium, directly in-
jure endothelium and affect platelets. Endothelial
cells can influence leukocytes, platelets and micro-
vascular function by release of adhesion and vasoac-
tive factors. Platelets also actively contribute to the
inflammatory reaction by releasing a spectrum of
biologically active substances which affect leuko-
cytes, endothelial cells as well as platelets them-
selves by stimulating their adhesion and aggrega-
tion [12]. As a result of the complex interaction
mentioned above, no-reflow phenomenon may oc-
cur even in the absence of a thrombus or microem-
bolization [13].
One of the earliest morphological changes ac-
companying reperfusion is myocardial cell swelling
with intracellular and interstitial oedema. There-
fore, compression of the microvascular bed by tis-
sue oedema is one of potential mechanisms affect-
ing tissue blood-flow, which must be taken under
consideration [13]. Moreover, endothelial cells
might be even more prone than myocardial cells to
damage caused by ischemia followed by reperfusion.
Local endothelial swelling and protrusion occlud-
ing capillary lumen is a common finding after reper-
fusion [14].
Undoubtedly, expression of the mechanisms
discussed above becomes more evident with pro-
longation of ischemia, enhancing the probability of
no-reflow. On the other hand, maintaining blood
flow in the infarct related vessel, even if severely
diminished, inhibits the cascade of events which
would lead to microcirculation damage [1]. Olszow-
ska et al. [6] proved the prognostic importance of
ischemia duration time and restoration of patency
of the infarct related artery for no-reflow occurrence
risk stratification. It should be noted though, that
no differences in the prevalence of no-reflow be-
tween patients treated with either primary or facil-
itated PCI were seen, despite higher incidence of
blood flow maintenance in the latter group [6].
Ischemic preconditioning might be capable of
reducing the risk for no-reflow by  preserving mi-
crovascular function and integrity. Some authors
suggest that application of short periods of artery
reocclusion after ischemia and reperfusion (post-
conditioning) can also improve vascular function and
reduce infarct size [14]. Studies by Olszowska et
al. [6] did not confirm the protective role of reccur-
rent ischemic episodes during the pre-infarction pe-
riod, though it is important to note that the group
of patients presenting with pre-infarction angina
was small.
Mechanisms underlying microvascular dys-
function after reperfusion in myocardial infarction
are very complex and only partially understood.
Studies defining risk factors of no-reflow phenom-
enon, like study by Olszowska et al. [6] published
in this issue of Cardiology Journal, composes an
important contribution in our knowledge, however
it is only a beginning of the way of prevention and
successful treatment of patients saddled with this
complication. Numerous and multidirectional at-
tempts to prevent no-reflow phenomenon have not
significantly succeeded yet [1]. In several small
studies performed in various patients’ cohorts
adenosine, verapamil, nicardipine, nitroprusside and
nicorandil have been shown to improve microvas-
cular perfusion [15]. Nevertheless, no therapy has
yet been proven to effectively prevent or to reverse
no-reflow in STEMI patients [3]. Promising results
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of single device studies, in particular those with use
of thrombectomy, have not been confirmed in rand-
omized trials [15]. Perhaps recently published re-
search by Ikeno et al. [16] will be a landmark one [17].
They have demonstrated effectiveness of a novel
strategy, targeted inhibition of the d isoform of pro-
tein kinase C (dPCK), to treat post-reperfusion no-
reflow in animal models. However, because of com-
plexity of pathophysiological mechanisms of no-re-
flow phenomenon, this promising method should be
explored further.
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